ImmunityBio's ANKTIVA meets primary endpoint in BCG-naive bladder cancer trial

What happened

On 9 November 2026, ImmunityBio reported that ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG met the primary efficacy endpoint in Cohort A of QUILT-2.005, a randomized, controlled trial of 370 BCG-naive patients with high-grade non-muscle-invasive bladder cancer (NMIBC) carrying carcinoma in situ, with or without papillary tumors ^[1]. The combination showed a statistically significant improvement over BCG alone, the most common adverse events were consistent with BCG alone, and no treatment-related deaths were reported ^[1]. Enrollment finished in February 2026; a March 2026 interim review by the independent data monitoring committee found no additional patients were needed to hold the trial's prespecified statistical power, and the database locked on 20 October 2026 ^[1]. The result was furnished to the SEC under a Regulation FD disclosure the same day ^[2] and mirrored on the company newsroom ^[6].

Why it matters

ANKTIVA's existing FDA approval sits in the BCG-unresponsive setting: patients whose disease returned after BCG, a relapsed and refractory population ^[5]. QUILT-2.005 moves the combination upstream into BCG-naive disease, the larger first-line population. The prior approvals rested on single-arm data from QUILT-3.032 (77 patients in Cohort A, 62% complete response) ^[4]; QUILT-2.005 is randomized and controlled against BCG alone, the comparison a skeptical reviewer and payer want to see ^[1]. If the supplemental BLA clears, ImmunityBio converts a salvage indication into a front-line option, with pricing and volume implications across the NMIBC market.

The company is already scaling commercially. Q3 2026 net product revenue was $48.7 million, up 53% year on year; nine-month US revenue reached $143.6 million, up 92%; and it held over $334.3 million in cash and marketable securities as of 30 September 2026 ^[3].

What to watch next

• The supplemental BLA is targeted for submission before the end of 2026 ^[1]. The public record names no review designation or action date. A standard FDA review of a supplemental BLA runs roughly six to ten months from acceptance, depending on whether priority review is granted, which on Prognyx's arithmetic (not a company or FDA figure) would place a decision somewhere between mid and late 2027 once the application is accepted. Treat that as indicative, not a committed date.
• The magnitude of benefit, the actual response rates versus BCG alone, is set for an upcoming medical congress rather than this disclosure ^[1].
• The BCG-unresponsive franchise keeps widening: on 14 October 2026 the FDA expanded the label to papillary-only tumors, so ANKTIVA now spans essentially all BCG-unresponsive NMIBC ^[4], and durability data published in The Journal of Urology on 16 October 2026 showed 84% cystectomy avoidance at 36 months among responders and a median complete-response duration of 26.6 months ^[3].

The now-what

For anyone developing in NMIBC, the signal is that ANKTIVA, the IL-15 receptor agonist already approved with BCG in the salvage setting, is no longer confined there and is pushing into first-line disease with randomized evidence against BCG alone ^[1][5]. A competing program can pull forward its own BCG-naive readout and build the head-to-head design against BCG alone that ImmunityBio has now set as the reference comparison. It can also compete on the measures ANKTIVA has not yet reported in the naive setting: response durability and cystectomy avoidance. The timing lever is the filing itself; a developer that submits sooner in BCG-naive disease blunts the head start ImmunityBio is reaching for.

What Prognyx could not verify

ImmunityBio has reported a statistically significant result but has not published the size of it: the response rates for the combination versus BCG alone are reserved for an upcoming medical congress, so the magnitude of benefit cannot be assessed from today's disclosure ^[1]. Every account of the topline, the press release, the Regulation FD 8-K and the company newsroom, traces to ImmunityBio; no analyst, competing publication or regulatory body has independently corroborated the QUILT-2.005 result as of this briefing ^[1][2][6]. Prognyx could not locate a ClinicalTrials.gov record for QUILT-2.005 in the set reviewed here to confirm its registered status, and no FDA review designation or action date for the planned supplemental BLA is yet on the public record.

Verdict: a credible challenge to BCG monotherapy in first-line NMIBC, still unquantified; competitors have until the Q4 2026 supplemental BLA filing and the congress data drop, both likely within months, to position before the effect size is public.